Oct 15 (Reuters) - Revance Therapeutics Inc said on Friday the U.S. Food and Drug Administration had declined to approve its DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines. (Reporting by Amruta Khandekar; Editing by Maju Samuel)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.315 USD | -7.14% | -13.06% | -62.51% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-62.51% | 372M | |
-2.86% | 87.31B | |
+2.63% | 40.86B | |
-21.44% | 29.36B | |
+58.56% | 24.49B | |
-14.37% | 17.31B | |
-18.67% | 11.62B | |
-15.61% | 11.31B | |
-44.02% | 11.26B | |
+5.17% | 8.31B |
- Stock Market
- Equities
- RVNC Stock
- News Revance Therapeutics, Inc.
- Revance Therapeutics : says U.S. FDA declined to approve frown line treatment